MUMBAI, India, Aug. 17 -- Intellectual Property India has published a patent application (202511007815 A) filed by International Center For Genetic Engineering And Biotechnology Icgeb on January 30, 2025, for Engineered Denv And Zikv Dimeric Envelope Glycoproteins Based On Consensus Sequences.
Inventors include Kumar, Sanjeev; and Chandele, Anmol.
The application for the patent was published on August 14, 2026, under issue no. 33/2026.
Abstract: The invention provides protein based, DNA-based, and protein nanoparticle vaccines useful in the prevention of Dengue and/or Zika virus infection. The vaccines comprise engineered dimeric envelope glycoproteins derived from consensus envelope sequences of dengue virus serotypes 1-4 and Zika virus. The envelope glycoproteins are designed to form stable dimers that present native-like quaternary epitopes, including envelope dimer epitopes associated with broadly neutralizing antibody responses. The disclosed vaccine compositions elicit robust and cross-reactive humoral immune responses while minimizing the induction of non-neutralizing or infection-enhancing antibodies. The invention further provides methods of inducing protective immunity against dengue and/or Zika virus in a subject by administering the disclosed vaccine compositions. Fig. 4
Disclaimer: Curated by HT Syndication.
